Gender and Race Differences in HeartMate3 Left Ventricular Assist Device as a Bridge to Transplantation
- PMID: 38180429
- DOI: 10.1016/j.jchf.2023.11.008
Gender and Race Differences in HeartMate3 Left Ventricular Assist Device as a Bridge to Transplantation
Abstract
Background: Gender and racial disparities exist after left ventricular assist device (LVAD) implantation. Compared with older devices, the HeartMate 3 (HM3) (Abbott Cardiovascular) has demonstrated improved survival. Whether HM3 differentially improves outcomes by gender or race and ethnic groups is unknown.
Objectives: The purpose of this study is to examine differences by gender and race in the use of HM3 among patients listed for heart transplantation (HT) and associated waitlist and post-transplant outcomes.
Methods: The authors examined all patients (20% women, 33% Black) who received LVADs as bridge to transplantation (BTT) between January 2018 and June 2020, in the OPTN (Organ Procurement and Transplantation Network) database. Trends in use of HM3 were evaluated by gender and race. Competing events of death/delisting and transplantation were evaluated using subdistribution hazard models. Post-transplant outcomes were evaluated using multivariate logistic regression adjusted for demographic, clinical, and donor characteristics.
Results: Of 11,524 patients listed for HT during the study period, 955 (8.3%) had HM3 implanted as BTT. Use of HM3 increased for all patients, with no difference in use by gender (P = 0.4) or by race (P = 0.2). Competing risk analysis did not demonstrate differences in transplantation or death/delisting in men compared with women (HT: adjusted HR [aHR]: 0.92 [95% CI: 0.70-1.21]; death/delisting: aHR: 0.91 [95% CI: 0.59-1.42]), although Black patients were transplanted fewer times than White patients (HT: aHR: 0.72 [95% CI: 0.57-0.91], death/delisting: aHR: 1.36 [95% CI: 0.98-1.89]). One-year post-transplant survival was comparable by gender (aHR: 0.52 [95% CI: 0.21-1.70]) and race (aHR: 0.76 [95% CI: 0.34-1.70]), with no differences in rates of stroke, acute rejection, or graft failure.
Conclusions: Use of HM3 among patients listed for HT has increased over time and by gender and race. Black patients with HM3 were less likely to be transplanted compared with White patients, but there were no differences in post-transplant outcomes between these groups or between men and women.
Keywords: HeartMate3; bridge to transplant; disparities; gender; heart failure; left ventricular assist device; race.
Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosure Dr Morris is supported by the American Heart Association, AHRQ (HS026081), the Woodruff Foundation, and the Association of Black Cardiologists; and has received consulting fees from Abbott, Acorai, BI Lilly, Cytokinetics, Edwards Lifesciences, Ionis, and Merck. Dr Patel is supported by the Stimulating Access to Research in Residency of the National Institutes of Health under Award Number R38AI140299. Dr Wang is supported by the National Heart, Lung and Blood Institute of the National Institutes of Health under award number 5T32HL007745. Dr Okoh is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number T32HL130025. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Similar articles
-
Early Outcomes After Heart Transplantation in Recipients Bridged With a HeartMate 3 Device.Ann Thorac Surg. 2019 Aug;108(2):467-473. doi: 10.1016/j.athoracsur.2019.01.084. Epub 2019 Mar 14. Ann Thorac Surg. 2019. PMID: 30880137
-
Racial disparities and outcomes of left ventricular assist device implantation as a bridge to heart transplantation.ESC Heart Fail. 2020 Oct;7(5):2744-2751. doi: 10.1002/ehf2.12866. Epub 2020 Jul 6. ESC Heart Fail. 2020. PMID: 32627939 Free PMC article.
-
Sex-Related Differences in Use and Outcomes of Left Ventricular Assist Devices as Bridge to Transplantation.JACC Heart Fail. 2019 Mar;7(3):250-257. doi: 10.1016/j.jchf.2019.01.008. JACC Heart Fail. 2019. PMID: 30819381
-
The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation.Health Technol Assess. 2005 Nov;9(45):1-132, iii-iv. doi: 10.3310/hta9450. Health Technol Assess. 2005. PMID: 16303098 Review.
-
"Durable left ventricular assist devices as a bridge to transplantation in The Old and The New World".J Heart Lung Transplant. 2024 Jun;43(6):1010-1020. doi: 10.1016/j.healun.2024.01.019. Epub 2024 Feb 14. J Heart Lung Transplant. 2024. PMID: 38360159 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
